Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tanezumab Clear all
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis Of The Hip

NCT00744471
View directory record Official record
Conditions
Arthritis, Osteoarthritis, Osteoarthritis, Hip
Interventions
tanezumab, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
99
States / cities
Mobile, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis of the Hip or Knee (2)

NCT00863304
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected

NCT01030640
View directory record Official record
Conditions
Osteoarthritis Pain, Chronic Low Back Pain, Pain Due to Interstitial Cystitis
Interventions
placebo, tanezumab
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 21, 2026, 10:42 PM EDT
Completed No phase listed Observational

A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth

NCT01362660
View directory record Official record
Conditions
Infant Developmental Assessment
Interventions
Unintentional exposure in utero
Other
Lead sponsor
Pfizer
Industry
Eligibility
Up to 15 Months
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Tempe, Arizona • Wildomar, California • Cutler Bay, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 2 Interventional Results available

RN624 For Pain Of Post-Herpetic Neuralgia

NCT00568321
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
RN624, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
31
States / cities
Anniston, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 2 Interventional Results available

An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis

NCT00601484
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
PF-04383119, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Peoria, Arizona • Fresno, California • Glendora, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tanezumab in Adults With Chronic Low Back Pain

NCT00876187
View directory record Official record
Conditions
Low Back Pain
Interventions
Tanezumab 20 mg IV, Placebo for naproxen, Tanezumab 10 mg IV, Tanezumab 5 mg IV, Placebo for tanezumab, Naproxen
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
135
States / cities
Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 101 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

NCT01087203
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Tanezumab, placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
48
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

NCT02697773
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Terminated Phase 3 Interventional Results available

Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients

NCT00960804
View directory record Official record
Conditions
Osteoarthritis
Interventions
Tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
18
States / cities
Atlantis, Florida • Fort Myers, Florida • South Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

NCT02528188
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions
NSAID, Tanezumab 2.5 mg, Tanezumab 5 mg
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
299
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 21, 2026, 10:42 PM EDT
Not listed Phase 2 Interventional

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

NCT04163419
View directory record Official record
Conditions
Schwannomatosis, Pain
Interventions
Tanezumab, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 21, 2026, 10:42 PM EDT
Terminated Phase 2 Interventional Results available

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

NCT00994890
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Tanezumab 2.5 mg, Tanezumab 5 mg, Tanezumab 10 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
100
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 2 Interventional

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

NCT00394563
View directory record Official record
Conditions
Osteoarthritis
Interventions
RN624 (PF-04383119), placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2009 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 3 Interventional Results available

Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies

NCT03031938
View directory record Official record
Conditions
Osteoarthritis, Cancer Pain, Recurrent Low Back Pain
Interventions
Investigational medical product (IMP) administered in parent study
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 2 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Sarasota, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 3 Interventional Results available

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement

NCT02674386
View directory record Official record
Conditions
Osteoarthritis
Interventions
Investigational Medical Product (IMP) administered in parent study
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 21, 2026, 10:42 PM EDT
Terminated Phase 3 Interventional Results available

Tanezumab In Osteoarthritis Of The Hip Or Knee

NCT00985621
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, oxycodone, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Terminated Phase 3 Interventional Results available

Tanezumab and Nerve Function In Arthritis Patients

NCT00863772
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
97
States / cities
Jonesboro, Arkansas • Aurora, Colorado • Centennial, Colorado + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Terminated Phase 2 Interventional Results available

A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

NCT00999518
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
Tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
122
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Terminated Phase 2 Interventional Results available

Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis

NCT01146561
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Naples, Florida • Wellington, Florida • Tupelo, Mississippi + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 2 Interventional Results available

RN624 In Adult Patients With Chronic Low Back Pain

NCT00584870
View directory record Official record
Conditions
Low Back Pain
Interventions
Naproxen, Placebo, PF-04383119 (RN624)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously

NCT00788294
View directory record Official record
Conditions
Healthy Volunteers
Interventions
tanezumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 21, 2026, 10:42 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study

NCT01089725
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Pain
Interventions
Placebo IV, Placebo SC, Tanezumab SC, Tanezumab IV
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
91
States / cities
Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 21, 2026, 10:42 PM EDT
Terminated Phase 2 Interventional Results available

Long Term Safety Study of Tanezumab in Chronic Low Back Pain

NCT00924664
View directory record Official record
Conditions
Low Back Pain
Interventions
Tanezumab 20 mg, Tanezumab 10 mg
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
149
States / cities
Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 21, 2026, 10:42 PM EDT